178 related articles for article (PubMed ID: 38509243)
21. Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.
Sestak I; Cuzick J; Dowsett M; Lopez-Knowles E; Filipits M; Dubsky P; Cowens JW; Ferree S; Schaper C; Fesl C; Gnant M
J Clin Oncol; 2015 Mar; 33(8):916-22. PubMed ID: 25332252
[TBL] [Abstract][Full Text] [Related]
22. Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer.
Godina C; Indira Chandran V; Barbachowska M; Tryggvadottir H; Nodin B; Visse E; Borgquist S; Jirström K; Isaksson K; Bosch A; Belting M; Jernström H
Transl Oncol; 2022 Aug; 22():101464. PubMed ID: 35660849
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
24. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Dowsett M; Sestak I; Lopez-Knowles E; Sidhu K; Dunbier AK; Cowens JW; Ferree S; Storhoff J; Schaper C; Cuzick J
J Clin Oncol; 2013 Aug; 31(22):2783-90. PubMed ID: 23816962
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer.
Zeng Y; Chen M; Ganesh S; Hu S; Chen H
PLoS One; 2020; 15(5):e0232235. PubMed ID: 32401768
[TBL] [Abstract][Full Text] [Related]
26. The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes.
Laenkholm AV; Jensen MB; Eriksen JO; Buckingham W; Ferree S; Nielsen TO; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):44-50. PubMed ID: 29202609
[TBL] [Abstract][Full Text] [Related]
27. Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.
Godina C; Tryggvadottir H; Bosch A; Borgquist S; Belting M; Isaksson K; Jernström H
Breast Cancer Res Treat; 2023 Jun; 199(2):335-347. PubMed ID: 37017811
[TBL] [Abstract][Full Text] [Related]
28. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
29. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
[TBL] [Abstract][Full Text] [Related]
30. PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Rasmussen BB; Knoop AS; Buckingham W; Ferree S; Schaper C; Nielsen TO; Haffner T; Kibøl T; Møller Talman ML; Bak Jylling AM; Tabor TP; Ejlertsen B
J Clin Oncol; 2018 Mar; 36(8):735-740. PubMed ID: 29369732
[TBL] [Abstract][Full Text] [Related]
31. Subtyping of male breast cancer by PAM50 and immunohistochemistry: a pilot study of a consecutive Danish cohort.
Christensen LG; Lautrup MD; Lyng MB; Möller S; Jylling AMB
APMIS; 2020 Sep; 128(9):523-530. PubMed ID: 32579768
[TBL] [Abstract][Full Text] [Related]
32. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B
Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900
[TBL] [Abstract][Full Text] [Related]
33. CpG island shore methylation regulates caveolin-1 expression in breast cancer.
Rao X; Evans J; Chae H; Pilrose J; Kim S; Yan P; Huang RL; Lai HC; Lin H; Liu Y; Miller D; Rhee JK; Huang YW; Gu F; Gray JW; Huang TM; Nephew KP
Oncogene; 2013 Sep; 32(38):4519-28. PubMed ID: 23128390
[TBL] [Abstract][Full Text] [Related]
34. Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.
Bonneterre J; Prat A; Galván P; Morel P; Giard S
Curr Med Res Opin; 2016 May; 32(5):835-9. PubMed ID: 26809116
[TBL] [Abstract][Full Text] [Related]
35. PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts.
Kensler KH; Sankar VN; Wang J; Zhang X; Rubadue CA; Baker GM; Parker JS; Hoadley KA; Stancu AL; Pyle ME; Collins LC; Hunter DJ; Eliassen AH; Hankinson SE; Tamimi RM; Heng YJ
Cancer Epidemiol Biomarkers Prev; 2019 Apr; 28(4):798-806. PubMed ID: 30591591
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-510 mediated negative regulation of Caveolin-1 in fibroblasts promotes aggressive tumor growth.
King B; Krisanits BA; Guo QJ; Blake B; Nogueira LM; Jolly G; Satterwhite A; Turner DP; Hoffman S; Evans-Knowell A; Findlay VJ
Front Immunol; 2023; 14():1116644. PubMed ID: 37822942
[TBL] [Abstract][Full Text] [Related]
37. Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.
Righi L; Cavallo MC; Gatti G; Monica V; Rapa I; Busso S; Albera C; Volante M; Scagliotti GV; Papotti M
Am J Clin Pathol; 2014 Jun; 141(6):816-27. PubMed ID: 24838326
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers.
Witkiewicz AK; Kline J; Queenan M; Brody JR; Tsirigos A; Bilal E; Pavlides S; Ertel A; Sotgia F; Lisanti MP
Cell Cycle; 2011 Jun; 10(11):1794-809. PubMed ID: 21521946
[TBL] [Abstract][Full Text] [Related]
39. Stromal Caveolin-1 and Caveolin-2 Expression in Primary Tumors and Lymph Node Metastases.
Gerstenberger W; Wrage M; Kettunen E; Pantel K; Anttila S; Steurer S; Wikman H
Anal Cell Pathol (Amst); 2018; 2018():8651790. PubMed ID: 29850392
[TBL] [Abstract][Full Text] [Related]
40. Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis.
Chen P; Mao X; Ma N; Wang C; Yao G; Ye G; Zhou D
Medicine (Baltimore); 2022 Aug; 101(31):e29877. PubMed ID: 35945759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
